Abstract

Lenalidomide constitutes a key component of therapeutic strategies for multiple myeloma, both in combination with dexamethasone and as maintenance treatment. However, patients exhibit substantial heterogeneity in response and duration of benefit. In order to focus only on the benefit of Lenalidomide, we retrospectively analyzed 186 MM patients treated with doublet, lenalidomide–dexamethasone and lenalidomide maintenance post-ASCT.